Literature DB >> 19834709

A rare trigger for macrophage activation syndrome.

Shikhar Agarwal1, Jayavani Moodley, Gati Ajani Goel, Karl S Theil, Syed S Mahmood, Richard S Lang.   

Abstract

Macrophage activation syndrome (MAS) is a disorder characterized by increased activation of mononuclear cells leading to phagocytosis of blood cell precursors in the bone marrow. We describe a case of MAS triggered by disseminated histoplasmosis occurring in a patient with Still's disease on long-term treatment with adalimumab.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19834709     DOI： 10.1007/s00296-009-1204-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   3.580


  6 in total

1.  High ferritin and low glycosylated ferritin may also be a marker of excessive macrophage activation.

Authors:  Olivier Lambotte; Patrice Cacoub; Nathalie Costedoat; Gisele Le Moel; Zahir Amoura; Jean-Charles Piette
Journal:  J Rheumatol       Date:  2003-05       Impact factor: 4.666

Review 2.  The macrophage activation syndrome: a new entity, a potentially fatal complication of rheumatic disorders.

Authors:  Stefka Iv Kuzmanova
Journal:  Folia Med (Plovdiv)       Date:  2005

3.  Macrophage activation syndrome: experience from a tertiary referral centre.

Authors:  L Pinto; F Kagalwala; S Singh; C Balakrishnan; S V Prabhu; S Khodaiji
Journal:  J Assoc Physicians India       Date:  2007-03

4.  Transient multiple cranial nerve involvement as a first sign of macrophage activation syndrome.

Authors:  L Rumbach; E Berger; L Tatu; T Moulin; J Y Cahn; J L Dupond; F Schillinger
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-03       Impact factor: 10.154

5.  Histoplasmosis-associated hemophagocytic syndrome: a case report.

Authors:  Alejandro Sanchez; Anna K Celaya; Anthony Victorio
Journal:  AIDS Read       Date:  2007-10

Review 6.  Macrophage activation syndrome.

Authors:  Angelo Ravelli
Journal:  Curr Opin Rheumatol       Date:  2002-09       Impact factor: 5.006
  6 in total
  6 in total

Review 1.  Treatment of adult-onset Still's disease: a review.

Authors:  Yvan Jamilloux; Mathieu Gerfaud-Valentin; Thomas Henry; Pascal Sève
Journal:  Ther Clin Risk Manag       Date:  2014-12-22       Impact factor: 2.423

Review 2.  Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab.

Authors:  Rahaf Baker; Jean W Liew; Paul D Simonson; Lori A Soma; Gordon Starkebaum
Journal:  Clin Rheumatol       Date:  2018-12-07       Impact factor: 2.980

3.  Macrophage Activation Syndrome Upon Initiation of Adalimumab in a Patient With Longstanding Rheumatoid Arthritis.

Authors:  Celestin Chicos; Milana Zirkiyeva; Sabiha Bandagi; Adriana Abrudescu
Journal:  Cureus       Date:  2021-01-20

4.  Possible macrophage activation syndrome following initiation of adalimumab in a patient with adult-onset Still's disease.

Authors:  Leila Souabni; Leila Dridi; Kawther Ben Abdelghani; Selma Kassab; Selma Chekili; Ahmed Laater; Leith Zakraoui
Journal:  Pan Afr Med J       Date:  2014-02-07

Review 5.  Biological therapy of traditional therapy-resistant adult-onset Still's disease: an evidence-based review.

Authors:  Sha Zhou; Jianjun Qiao; Juan Bai; Yinhua Wu; Hong Fang
Journal:  Ther Clin Risk Manag       Date:  2018-01-24       Impact factor: 2.423

6.  Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts.

Authors:  Serena Colafrancesco; Maria Manara; Alessandra Bortoluzzi; Teodora Serban; Gerolamo Bianchi; Luca Cantarini; Francesco Ciccia; Lorenzo Dagna; Marcello Govoni; Carlomaurizio Montecucco; Roberta Priori; Angelo Ravelli; Paolo Sfriso; Luigi Sinigaglia
Journal:  Arthritis Res Ther       Date:  2019-12-11       Impact factor: 5.156
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.